Ticker Details
Halozyme Therapeutics, Inc. Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.
IPO Date:	March 16, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$7.95B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.40 | 2.13%
Avg Daily Range (30 D):	$0.82 | 1.25%
Avg Daily Range (90 D):	$1.05 | 1.50%

Institutional Daily Volume
Avg Daily Volume:	.98M
Avg Daily Volume (30 D):	1.17M
Avg Daily Volume (90 D):	1.52M

Trade Size
Avg Trade Size (Sh.):	103
Avg Trade Size (Sh.) (30 D):	51
Avg Trade Size (Sh.) (90 D):	58

Institutional Trades
Total Institutional Trades:	10,632
Avg Institutional Trade:	$3.14M
Avg Institutional Trade (30 D):	$5.58M
Avg Institutional Trade (90 D):	$5.78M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.31M
Avg Closing Trade (30 D):	$18.91M
Avg Closing Trade (90 D):	$20.77M
Avg Closing Volume:	165.77K

News

Mar 19, 2026 @ 8:00 PM Acumen Pharmaceuticals to Report Fourth Quarter an... Source: Na

Mar 10, 2026 @ 8:00 PM Acumen Pharmaceuticals to Participate in the Stife... Source: Na

Jan 28, 2026 @ 6:58 PM Halozyme Therapeutics Projects Sustained Growth We... Source: Vandana Singh

Dec 16, 2025 @ 6:17 PM Immunotherapy Breakthroughs Turn Cold GI Tumors Ho... Source: Prnewswire

Nov 5, 2025 @ 10:12 PM Renaissance Group Opens New $35M Position in Haloz... Source: Josh Kohn-Lindquist

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.64	$-1.16	$2.64
Diluted EPS	$2.56	$-1.12	$2.56
Revenue	$1.4B	$451.77M	$1.4B
Gross Profit	$1.17B	$373M	$1.17B
Net Income / Loss	$316.89M	$-141.59M	$316.89M
Operating Income / Loss	$469.01M	$-92.89M	$469.01M
Cost of Revenue	$228.77M	$78.77M	$228.77M
Net Cash Flow	$20.57M	$-283.24M	$20.57M
PE Ratio	26.49